Show simple item record

dc.contributor.authorCameron, LB
dc.contributor.authorJiang, DHS
dc.contributor.authorMoodie, K
dc.contributor.authorMitchell, C
dc.contributor.authorSolomon, B
dc.contributor.authorParameswaran, BK
dc.date.accessioned2020-12-21T04:28:53Z
dc.date.available2020-12-21T04:28:53Z
dc.date.issued2017-02-16
dc.identifierpii: 10.1186/s40644-017-0109-5
dc.identifier.citationCameron, L. B., Jiang, D. H. S., Moodie, K., Mitchell, C., Solomon, B. & Parameswaran, B. K. (2017). Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. CANCER IMAGING, 17 (1), https://doi.org/10.1186/s40644-017-0109-5.
dc.identifier.issn1470-7330
dc.identifier.urihttp://hdl.handle.net/11343/257641
dc.description.abstractBACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - rearranged advanced non-small cell lung cancer (NSCLC) treated with Crizotinib. Many of these lesions undergo spontaneous resolution despite developing complex features on imaging. We assess the incidence and patterns of evolution of Crizotinib Associated Renal Cysts [CARCs] at our institute and provide histopathology correlation of their benign nature. METHODS: A retrospective analysis of renal lesions in computerised tomography (CT) scans of 35 patients with advanced ALK-rearranged NSCLC who had been prescribed crizotinib at our institution was performed by three radiologists, who analysed the evolution of these lesions, particularly for pre-defined significant and complex changes. RESULTS: Of 26 patients eligible for this analysis, 4 (15%) had cysts at baseline that remained stable on crizotinib treatment while 11(42%) developed significant change in 28 renal cysts. Commonest pattern of cyst evolution was enlargement from baseline followed by spontaneous regression (17/28 lesions) while other patterns noted were stable lesions, regression from baseline and ongoing enlargement. The median maximum size reached was 23 mm (range 9 - 67 mm) after a median of 178 days (160 to 1342) on crizotinib. Complex change occurred in 12 cysts, in 7/26 (27%) patients and within 60 days of starting Crizotinib in 10 cysts. Imaging features were falsely concerning for malignancy or abscess in 4/26 patients. CONCLUSION: Most CARCs resolve spontaneously, or have a benign evolution despite enlargement and other features concerning for malignancy or infection on imaging. This unusual manifestation of chemotherapy should be recognised, particularly by radiologists, so that inappropriate treatment decisions are avoided.
dc.languageEnglish
dc.publisherE-MED
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCrizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
dc.typeJournal Article
dc.identifier.doi10.1186/s40644-017-0109-5
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleCancer Imaging
melbourne.source.volume17
melbourne.source.issue1
dc.rights.licenseCC BY
melbourne.elementsid1185277
melbourne.contributor.authorSolomon, Benjamin
dc.identifier.eissn1740-5025
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record